STEPS AFTER GRANTING THE MARKETING AUTHORISATION 
For procedures finalised after 1 September 2003 please refer to module 8B. 
Scope 
Application 
number 
Type of 
modification1 
Demonstration of TSE compliance 
Change in the insulin glargine production process 
Change to the manufacturing process for the active substance 
New presentation(s) 
Addition of a new volume vial of 10 ml 
Change in the batch size of finished product 
Change in supplier of an intermediate compound used in 
manufacture of the active substance 
II/0001 
II/0002 
II/0003 
II/0004 
I/0005 
I/007 
II 
II 
II 
II 
I/II 
I 
Notification/ 
Opinion 
issued on2 
26/04/2001 
27/06/2001 
27/06/2001 
Commission 
Decision 
Issued/amended 
on 
- 
- 
- 
25/04/2002 
09/08/2002 
25/04/2003 
- 
19/07/2003 
1 In accordance with Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended: I refers 
to a minor variation (Type I variation); II refers to a major variation (Type II variation); I/II refers to a 
minor variation following the procedure set out in Article 6, 7 and 8 of the Regulation; X refers to an 
Annex II application. 
T refers to a transfer of a Marketing Authorisation in accordance with Commission Regulation (EC) 
No 2141/96 of 7 November 1996.  
N refers to a notification in accordance with Article 61(3) of Directive 2001/83/EC of 6 November 
2001. 
2 For Notifications and Type I variations, the date of entry into force of the change is the EMEA Notification 
date. The Commission Decision will be amended accordingly. 
1/1 
ï£©EMEA 2005 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                      
 
 
